糖突变酶1缺乏被误诊为拉伦综合征
Seyit Ahmet Uçaktürk1, Emre Özer2, Ahmet Cevdet Ceylan3
1Department of Pediatric Endocrinology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.
Journal of pediatric endocrinology & metabolism : JPEM
|October 16, 2025
概括
血糖化 (CDG) 的先天性疾病,特别是糖突变酶1缺乏 (PGM1-CDG),可以模仿生长激素不敏感性 (GHI). 早期诊断和复合人体胰岛素样生长因子-1 (rhIGF-1) 治疗改善了这个患者的生长.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 内分泌学 在内分泌学.
背景情况:
- 蛋白质糖化对蛋白质的稳定性和相互作用至关重要.
- 糖化基因的突变导致糖化基因 (CDG) 的先天性疾病,导致多系统性疾病.
- 糖突变酶1缺乏症 (PGM1-CDG) 是一种由PGM1酶缺乏症引起的CDG.
研究的目的:
- 报告一个PGM1-CDG病例,最初被误诊为生长激素不敏感 (GHI).
- 突出PGM1-CDG的诊断挑战和治疗益处.
- 强调在患有GHI类症状和多系统性疾病的患者中考虑CDG的重要性.
主要方法:
- 一个案例展示了一个2岁至11个月的雌性低血糖症和矮身.
- 诊断评估包括生长激素和IGF-1测试,揭示了与GHI一致的发现.
- 开始使用复合人体胰岛素样生长因子-1 (rhIGF-1) 治疗,基因测试证实了PGM1-CDG.
主要成果:
- 患者表现出高基底和刺激生长激素水平,低IGF-1,模仿GHI.
- rhIGF-1疗法导致显著的身高增长和临床改善.
- 观察到肌酸激酶,转氨酶水平升高和心肌病,有助于PGM1-CDG诊断.
结论:
- PGM1-CDG可以呈现出与GHI无法区分的临床和实验室特征.
- 多系统性参与,包括肝病,CK升高和心肌病,应促使考虑CDG.
- 成功的rhIGF-1疗法强调了其在管理与PGM1-CDG相关的生长障碍方面的潜力.
相关概念视频
Inborn Errors of Metabolism
693
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
693
Glucose Transporters
27.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.2K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Overview of Protein Metabolism
3.6K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
3.6K
Cystic Fibrosis: Pathogenesis
710
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
710
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180


